Insider · SEC Forms 3, 4, 5
CIK 1494730
All transactions
Every Form 4 row this person reported, newest first
Insider · SEC Forms 3, 4, 5
Every Form 4 row this person reported, newest first
Heerma Peter (CIK 1789617) reported 27 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-17). Recent activity: Buy TVTX (39,283 shares), Sell TVTX (8,282 shares), Buy TVTX (36,526 shares), Sell TVTX (71,938 shares), Sell TVTX (27,421 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Buy | 39,283 | $1.1M |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Sell | 8,282 | $538,917 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Buy | 36,526 | $326,177 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Sell | 71,938 | $4.5M |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Sell | 27,421 | $1.7M |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Sell | 1,400 | $89,113 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Sell | 1,431 | $93,458 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Buy | 1,381 | $30,934 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Buy | 55,000 | $850,300 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Buy | 17,717 | $476,233 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Sell | 93,604 | $5.9M |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Sell | 79,113 | $5.0M |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Buy | 8,282 | $185,517 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | Buy | 100,000 | $1.1M |
| 2026-05-06 | Travere Therapeutics, Inc. (TVTX) | CHIEF COMMERCIAL OFFICER | Buy | 4,250 | $0 |
| 2026-05-06 | Travere Therapeutics, Inc. (TVTX) | CHIEF COMMERCIAL OFFICER | Sell | 2,174 | $101,417 |
| 2026-04-15 | Travere Therapeutics, Inc. (TVTX) | CHIEF COMMERCIAL OFFICER | Buy | 14,000 | $0 |
| 2026-04-15 | Travere Therapeutics, Inc. (TVTX) | CHIEF COMMERCIAL OFFICER | Sell | 7,215 | $302,525 |
| 2026-02-03 | Travere Therapeutics, Inc. (TVTX) | CHIEF COMMERCIAL OFFICER | Buy | 26,120 | $0 |
| 2026-02-03 | Travere Therapeutics, Inc. (TVTX) | CHIEF COMMERCIAL OFFICER | Sell | 7,310 | $234,797 |
| 2025-12-29 | Travere Therapeutics, Inc. (TVTX) | CHIEF COMMERCIAL OFFICER | Sell | 4,980 | $199,200 |
| 2025-11-04 | Travere Therapeutics, Inc. (TVTX) | CHIEF COMMERCIAL OFFICER | Sell | 5,591 | $195,685 |
| 2025-11-04 | Travere Therapeutics, Inc. (TVTX) | CHIEF COMMERCIAL OFFICER | Sell | 1,078 | $0 |
| 2025-10-30 | Travere Therapeutics, Inc. (TVTX) | CHIEF COMMERCIAL OFFICER | Sell | 2,662 | $79,860 |
| 2025-09-24 | Travere Therapeutics, Inc. (TVTX) | CHIEF COMMERCIAL OFFICER | Sell | 891 | $0 |
Source: SEC Form 4 filings · as of 2026-09-17